Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
复制标题
DOI：
10.1155/2020/5463451
复制
发表时间：
2020-06-15
影响因子：
2.5
通讯作者：
van de Garde, E. M. W.
中科院分区：
文献类型：
--
作者：
Daniels, K.;van der Nat, P. B.;van de Garde, E. M. W.
背景最近，ocrelizumab（Ocrevus（R））被批准用于治疗原发性进行性多发性硬化症（PPMS）的基础上，从奥拉托里奥临床试验的数据。关于ocrelizumab临床有效性的真实数据尚未收集。本研究的目的是提供关于ocrelizumab在现实世界中诊断为PPMS的患者的临床有效性的数据。我们对2018年4月至2018年12月31日期间在圣安东尼医院（荷兰乌得勒支/纽韦根）开始ocrelizumab治疗的所有PPMS患者（n=21）进行了一项回顾性队列研究。主要结局是ocrelizumab治疗前与治疗后残疾恶化率（从首次ocrelizumab给药前96周至首次ocrelizumab给药后24周）。治疗期间的残疾恶化率与治疗前的残疾恶化率存在显著差异（较低）（Z=-2.81，p
Background. Recently, ocrelizumab (Ocrevus (R)) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective. The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods. We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n=21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results. Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z=-2.81,p